CLC-3001

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameCLC-3001
Drug Alias Namenitric oxide and pioglitazone based hybrid molecule (Cardiolynx)CLC-3001CLC-3000
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsNitric oxide stimulantsInsulin sensitizers
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCardiolynx Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCardiolynx Ag
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A